Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT06337162

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

A Pilot Study of Neoadjuvant INCB099280 in Patients With Hepatocellular Carcinoma Awaiting Liver Transplant

Status
Withdrawn
Phase
Phase 1
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Abramson Cancer Center at Penn Medicine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant.

Conditions

Interventions

TypeNameDescription
DRUGINCB099280400 mg Tablet

Timeline

Start date
2024-05-01
Primary completion
2027-05-01
Completion
2028-09-01
First posted
2024-03-29
Last updated
2024-08-09

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06337162. Inclusion in this directory is not an endorsement.

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) (NCT06337162) · Clinical Trials Directory